profit from every €100 of sales.
€0€100
Eckert & Ziegler
€15.34+5.79% today
+2.5% since Dec 21, 25
1-year low €12.001-year high €16.52
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €19.69 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Eckert & Ziegler sold, what it kept, and what it did with the cash.
Sales went from €222 million in 2022 to €312 million in 2025, with €48.8 million of profit last year.
SalesProfit
Eckert & Ziegler handed back 34% of the cash it generated last year.
€10M
Free cash flow 2025€32M
Bought back its own shares€638,000
Paid as dividends€10M
Cash vs. debt€129M vs. €45M
Eckert & Ziegler vs. similar companies
Eckert & Ziegler grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Eckert & Ziegler | 19.7× · Fair price | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Eckert & Ziegler's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 222 | 246 | 296 | 312 | |
| 107 | 113 | 143 | 153 | |
| 46 | 47 | 67 | 75 | |
| 58 | 60 | 81 | 94 | |
| 29 | 26 | 33 | 49 | |
| 0.47 | 0.42 | 0.53 | 0.78 | |
| 48.0% | 46.1% | 48.4% | 49.0% | |
| 20.7% | 18.9% | 22.7% | 24.1% | |
| 13.2% | 10.7% | 11.2% | 15.6% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 407 | 439 | 442 | 458 |
| Cash | 83 | 68 | 118 | 129 |
| Total debt | 50 | 56 | 55 | 45 |
| Total liabilities | 194 | 215 | 217 | 205 |
| 212 | 222 | 223 | 252 | |
| 62 | 62 | 63 | 63 | |
| 12.6% | 11.6% | 15.6% | 18.2% | |
| 13.8% | 11.8% | 14.9% | 19.4% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 34 | 47 | 67 | 58 | |
| 27 | 26 | 17 | 26 | |
| 7 | 21 | 49 | 32 | |
| Dividends paid | 10 | 10 | 1 | 10 |
| 0 | 0 | 1 | 1 | |
| – | 1 | 2 | – |
Valuation
- 19.7×
- –
- 1.07
- 3.8×
- 3.1×
- 29.6×
- 9.3×
- 3.4%
- 5.1%
- 1.1%
Profitability
- 49.0%
- 24.1%
- 15.6%
- –
- 18.2%
- 14.5%
- –
- –
- –
- –
Growth
- +12.0%
- +18.4%
- –
- –
- +0.2%
Financial health
- -0.9×
- 0.18
- –
- 17.2×
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 946
Top 17%of 872
Top 30%of 563
Top 47%of 868
Top 32%of 986
1.1%of the share price, paid each year
On $1,000 invested$11a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
21.4% of its profit
Room to growStretchedMore than it earns: 32.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
69Pass
Benjamin Graham
57No pass
Philip Fisher
75Pass
Peter Lynch
72Pass
Joel Greenblatt
50No pass
Charlie Munger
67Pass
Terry Smith
56No pass
Questions about Eckert & Ziegler
Is Eckert & Ziegler a good stock to buy?
A solid business at a fair price. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Eckert & Ziegler AI analysis
What does Eckert & Ziegler do?
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. It is in Medical Devices, based in Berlin, Germany, with 1,100 employees.
Does Eckert & Ziegler pay a dividend?
Yes. At today's price the dividend is 1.1% a year, about 21% of its yearly profit. In 2025 it paid out €10.4 million in dividends.
Is Eckert & Ziegler stock halal?
Yes. Eckert & Ziegler passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
Who are Eckert & Ziegler's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Eckert & Ziegler's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.